National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/14537

TDMS Study 99039-02 Pathology Tables

NTP Experiment-Test: 99039-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                    TRANSGENIC MODEL EVALUATION II  (ACESULFAME POTASSIUM)                 Date: 02/21/03
Route: DOSED FEED                                                                                                 Time: 10:29:55

                                                      FINAL#3/P53 +/- MICE




       Facility:  BIORELIANCE

       Chemical CAS #:  55589-62-3

       Lock Date:  07/20/01

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 99039-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                    TRANSGENIC MODEL EVALUATION II  (ACESULFAME POTASSIUM)                 Date: 02/21/03  
Route: DOSED FEED                                                                                                 Time: 10:29:55  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P53+/-(C57BL/6) FEMALE                    VEHICLE      0.3 %        1.0 %        3.0 %                                     
                                                   CONTROL                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15                                     
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 1                         1                                                  
    Natural Death                                                   1                         1                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                11           14           14           13                                     
    Accidently Killed                                  3                                      1                                     
                                                                                                                                    
  Animals Examined Microscopically                    15            1            2           15                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Mesentery                                                       (1)                                                              
      Sarcoma                                                       1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)                                   (15)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Tissue NOS                                         (1)                                                                           
      Pelvic, Osteosarcoma, Metastatic, Bone           1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 99039-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                    TRANSGENIC MODEL EVALUATION II  (ACESULFAME POTASSIUM)                 Date: 02/21/03  
Route: DOSED FEED                                                                                                 Time: 10:29:55  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P53+/-(C57BL/6) FEMALE                    VEHICLE      0.3 %        1.0 %        3.0 %                                     
                                                   CONTROL                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                                                                (1)                                    
      Pancreatic, Histiocytic Sarcoma                                                         1 (100%)                              
   Spleen                                             (15)                                   (14)                                   
      Histiocytic Sarcoma                                                                     1 (7%)                                
   Thymus                                             (15)                                   (14)                                   
      Histiocytic Sarcoma                                                                     1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (15)                      (1)          (13)                                   
      Osteosarcoma                                                               1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (15)                                   (14)                                   
      Femur, Osteosarcoma                              1 (7%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)                                   (15)                                   
      Osteosarcoma, Metastatic, Bone                   1 (7%)                                                                       
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 99039-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                    TRANSGENIC MODEL EVALUATION II  (ACESULFAME POTASSIUM)                 Date: 02/21/03  
Route: DOSED FEED                                                                                                 Time: 10:29:55  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P53+/-(C57BL/6) FEMALE                    VEHICLE      0.3 %        1.0 %        3.0 %                                     
                                                   CONTROL                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(1)         *(2)         *(15)                                   
      Histiocytic Sarcoma                                                                     1 (7%)                                
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 99039-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                    TRANSGENIC MODEL EVALUATION II  (ACESULFAME POTASSIUM)                 Date: 02/21/03  
Route: DOSED FEED                                                                                                 Time: 10:29:55  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P53+/-(C57BL/6) FEMALE                    VEHICLE      0.3 %        1.0 %        3.0 %                                     
                                                   CONTROL                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             1           1           1           2                                       
     Total Primary Neoplasms                            1           1           1           2                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                                                                                              
     Total Benign Neoplasms                                                                                                         
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1           1           1           2                                       
     Total Malignant Neoplasms                          1           1           1           2                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              1                                                                           
     Total Metastatic Neoplasm                          2                                                                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 99039-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                    TRANSGENIC MODEL EVALUATION II  (ACESULFAME POTASSIUM)                 Date: 02/21/03  
Route: DOSED FEED                                                                                                 Time: 10:29:55  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P53+/-(C57BL/6) MALE                      VEHICLE      0.3 %        1.0 %        3.0 %                                     
                                                   CONTROL                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15                                     
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 1                                      1                                     
  Survivors                                                                                                                         
    Accidently Killed                                  3                         1                                                  
    Terminal Sacrifice                                11           15           14           14                                     
                                                                                                                                    
  Animals Examined Microscopically                    15                         1           15                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 99039-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                    TRANSGENIC MODEL EVALUATION II  (ACESULFAME POTASSIUM)                 Date: 02/21/03  
Route: DOSED FEED                                                                                                 Time: 10:29:55  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P53+/-(C57BL/6) MALE                      VEHICLE      0.3 %        1.0 %        3.0 %                                     
                                                   CONTROL                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)                      (1)          (15)                                   
      Pinna, Hemangiosarcoma                                                     1 (100%)                                           
      Subcutaneous Tissue, Fibrosarcoma                                                       1 (7%)                                
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 99039-02  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                    TRANSGENIC MODEL EVALUATION II  (ACESULFAME POTASSIUM)                 Date: 02/21/03  
Route: DOSED FEED                                                                                                 Time: 10:29:55  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P53+/-(C57BL/6) MALE                      VEHICLE      0.3 %        1.0 %        3.0 %                                     
                                                   CONTROL                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)                                     1           1                                       
     Total Primary Neoplasms                                                    1           1                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                                                                                              
     Total Benign Neoplasms                                                                                                         
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                       1           1                                       
     Total Malignant Neoplasms                                                  1           1                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------                                           
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.